At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 102 enrolled
Drug / intervention
Anakinra +1 moredrug
Likely dose
Anakinra 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effects of Interleukin-1 Blockade On Exercise Capacity In Patients With Recently Decompensated Systolic Heart Failure
In Brief
A Phase 2 clinical trial evaluating Anakinra and Placebo for Heart Failure, Systolic and Inflammation. Completed, enrolled 102 participants across 1 site.
Detailed Summary
REDHART2 is a randomized, double-blinded, placebo-controlled trial to determine the effects of Anakinra on peak aerobic exercise capacity measured with a cardiopulmonary test after 24 weeks in patients with recently decompensated systolic heart failure and increased systemic inflammation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Failure, Systolic, Inflammation
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
Enrollment StartJan 2019
First PostedJan 2019
Primary CompletionJul 2024
TodayJul 2026
First PostedJan 8, 2019
Enrollment StartJan 4, 2019
Primary CompletionJul 22, 2024
TodayJul 2, 2026
Enrollment to primary: 5.5 yearsPosted 7.5 years ago
Interventions
Anakinradrug
100 mg subcutaneous injection, daily for 24 weeks
Placebodrug
subcutaneous injection, daily for 24 weeks